Bristol Glucophage Managed Care Discounts Will Encourage Switches
Executive Summary
Bristol-Myers Squibb is looking to its managed care contracting for Glucophage to increase growth in the newer once-daily and combination formulations of the antidiabetic.
You may also be interested in...
Bristol R&D In Brief
Bristol Glucophage exclusivity: Bristol is unable to give 2002 guidance due to uncertainty surrounding Glucophage exclusivity, CEO Peter Dolan told a Nov. 7 update on the company's R&D program. "As this could be a meaningful contributor to our sales and earnings and because we maintain that our pediatric label legally entitles us an additional three years of exclusivity, any statements or stated assumptions about 2002 for the Glucophage family...could jeopardize this rapidly evolving situation." Bristol "appears to be close to knowing whether there'll be legislation affecting our rights...and what the FDA will be doing"...
Bristol R&D In Brief
Bristol Glucophage exclusivity: Bristol is unable to give 2002 guidance due to uncertainty surrounding Glucophage exclusivity, CEO Peter Dolan told a Nov. 7 update on the company's R&D program. "As this could be a meaningful contributor to our sales and earnings and because we maintain that our pediatric label legally entitles us an additional three years of exclusivity, any statements or stated assumptions about 2002 for the Glucophage family...could jeopardize this rapidly evolving situation." Bristol "appears to be close to knowing whether there'll be legislation affecting our rights...and what the FDA will be doing"...
Pediatric Bill Toll-Free Adverse Event Hotline Is Of Concern To Pharmacy
The retail pharmacy trade associations are urging the House leadership to delete language creating an adverse event reporting hotline from the pediatric exclusivity bill